LUNGevity Foundation Applauds FDA Approval of Zykadia™ (ceritinib) as Additional Tool in Arsenal for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
LUNGevity Foundation Applauds FDA Approval of Zykadia™ (ceritinib) as Additional Tool in Arsenal for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Ceritinib (brand name Zykadia™) will be used for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (brand name Xalkori™) PR Newswire WASHINGTON, May 1, 2014 WASHINGTON , May 1, 2014 /PRNewswire-USNewswire/ — LUNGevity Foundation applauds the FDA approval of Zykadia™ for the subset of anaplastic lymphoma kinase-positive (ALK+) patients with advanced cases of non-small cell lung cancer who have progressed on or are intolerant to crizotinib. Zykadia™ was given breakthrough therapy designation in March 2013 and received FDA approval under the agency’s accelerated approval program. Having a range of ALK inhibitors provides important options for these patients […]